Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alfresa Holdings Corporation (2784.T)
Tokyo, JP
Alfresa Holdings Corporation, a Japanese company established in Tokyo in 2003, operates globally through its subsidiaries, specializing in the production, wholesale distribution, marketing, and international trade of pharmaceuticals, diagnostic reagents, and medical equipment. A significant part of its operations involves the wholesale supply of ethical pharmaceuticals, diagnostic reagents, and medical devices to healthcare providers including hospitals, clinics, and dispensing pharmacies. The company also manages the wholesale distribution of self-medication products, such as over-the-counter drugs, nutritional supplements, and health foods, to drugstores and pharmacies. Furthermore, Alfresa is engaged in the manufacturing and commercialization of active pharmaceutical ingredients, various pharmaceuticals, diagnostic reagents, and medical devices, alongside providing contract manufacturing services for pharmaceutical goods. Its medical-related division also encompasses the management of dispensing pharmacies and other associated healthcare activities.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.55% | +2.68% | -1.34% | -4.38% | +3.42% | -2.79% | +21.43% | +9.73% | +37.57% | +5.80% | +165.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+4.8% Q1'26: +6.0% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+55.7% ★ Q1'26: +487.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+0.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.2% Q1'26: +0.9% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+6.9% ★ Q1'26: +4.9% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-2.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.70× ★ Q1'26: 0.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 3 EPS Ana. |
Mar 2027 3 Rev. Ana. 2 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.42T
est: 2.42T (+0.1%)
|
2.58T
est: 2.58T (-0.2%)
|
2.55T
est: 2.57T (-0.6%)
|
2.60T
est: 2.61T (-0.2%)
|
2.64T
est: 2.63T (+0.3%)
|
2.70T
est: 2.68T (+0.6%)
|
2.61T
est: 2.60T (+0.4%)
|
2.59T
est: 2.57T (+0.5%)
|
2.70T
est: 2.70T (-0.1%)
|
2.86T
est: 2.87T (-0.5%)
|
2.96T
est: 2.96T (+0.0%)
|
3.10T
3.09T – 3.11T
+4.7% YoY
|
3.19T
3.18T – 3.20T
+2.8% YoY
|
3.27T
3.23T – 3.29T
+2.6% YoY
|
3.35T
3.35T – 3.35T
+2.4% YoY
|
3.50T
3.47T – 3.51T
+4.5% YoY
|
| EBITDA |
38.60B
est: 48.38B (-20.2%)
|
56.12B
est: 51.67B (+8.6%)
|
44.25B
est: 51.36B (-13.8%)
|
52.32B
est: 52.16B (+0.3%)
|
55.54B
est: 52.66B (+5.5%)
|
59.42B
est: 53.65B (+10.8%)
|
39.80B
est: 52.01B (-23.5%)
|
41.92B
est: 51.50B (-18.6%)
|
43.45B
est: 54.01B (-19.5%)
|
51.98B
est: 50.60B (+2.7%)
|
53.20B
est: 52.16B (+2.0%)
|
54.63B
54.48B – 54.84B
+4.7% YoY
|
56.14B
55.96B – 56.40B
+2.8% YoY
|
57.58B
56.91B – 57.92B
+2.6% YoY
|
58.95B
58.95B – 58.95B
+2.4% YoY
|
61.58B
61.12B – 61.91B
+4.5% YoY
|
| EBIT |
29.22B
est: 36.67B (-20.3%)
|
45.27B
est: 39.16B (+15.6%)
|
33.23B
est: 38.92B (-14.6%)
|
41.76B
est: 39.53B (+5.6%)
|
44.78B
est: 39.91B (+12.2%)
|
47.65B
est: 40.66B (+17.2%)
|
27.93B
est: 39.42B (-29.1%)
|
29.09B
est: 39.03B (-25.5%)
|
30.15B
est: 40.93B (-26.3%)
|
38.46B
est: 36.84B (+4.4%)
|
38.27B
est: 37.98B (+0.8%)
|
39.78B
39.67B – 39.94B
+4.7% YoY
|
40.88B
40.75B – 41.07B
+2.8% YoY
|
41.93B
41.44B – 42.18B
+2.6% YoY
|
42.92B
42.92B – 42.92B
+2.4% YoY
|
44.84B
44.51B – 45.08B
+4.5% YoY
|
| Net Income |
22.92B
est: 15.53B (+47.6%)
|
34.98B
est: 25.36B (+37.9%)
|
30.89B
est: 23.39B (+32.1%)
|
35.59B
est: 26.82B (+32.7%)
|
41.73B
est: 36.33B (+14.9%)
|
40.27B
est: 32.79B (+22.8%)
|
24.50B
est: 19.01B (+28.9%)
|
32.18B
est: 21.48B (+49.8%)
|
25.79B
est: 21.63B (+19.2%)
|
29.56B
est: 28.87B (+2.4%)
|
27.39B
est: 30.22B (-9.4%)
|
37.04B
35.61B – 37.73B
+22.6% YoY
|
28.30B
27.26B – 28.96B
-23.6% YoY
|
30.05B
26.06B – 32.71B
+6.2% YoY
|
30.43B
28.02B – 32.81B
+1.2% YoY
|
34.78B
34.44B – 35.02B
+14.3% YoY
|
| SGA |
128.83B
est: 137.89B (-6.6%)
|
143.57B
est: 147.27B (-2.5%)
|
141.47B
est: 146.37B (-3.3%)
|
143.96B
est: 148.66B (-3.2%)
|
148.43B
est: 150.10B (-1.1%)
|
150.20B
est: 152.89B (-1.8%)
|
145.31B
est: 148.24B (-2.0%)
|
147.85B
est: 146.78B (+0.7%)
|
150.02B
est: 153.93B (-2.5%)
|
155.70B
est: 161.27B (-3.5%)
|
162.54B
est: 166.24B (-2.2%)
|
174.11B
173.63B – 174.80B
+4.7% YoY
|
178.92B
178.35B – 179.76B
+2.8% YoY
|
183.54B
181.38B – 184.62B
+2.6% YoY
|
187.87B
187.87B – 187.87B
+2.4% YoY
|
196.28B
194.80B – 197.32B
+4.5% YoY
|
| EPS |
102.48
est: 83.67 (+22.5%)
|
158.99
est: 136.63 (+16.4%)
|
142.57
est: 126.00 (+13.2%)
|
164.25
est: 144.50 (+13.7%)
|
195.91
est: 195.70 (+0.1%)
|
190.26
est: 176.63 (+7.7%)
|
115.75
est: 102.43 (+13.0%)
|
153.57
est: 115.70 (+32.7%)
|
127.42
est: 116.15 (+9.7%)
|
154.13
est: 159.03 (-3.1%)
|
147.54
est: 166.46 (-11.4%)
|
202.74
195.92 – 207.54
+21.8% YoY
|
155.59
149.97 – 159.29
-23.3% YoY
|
161.28
143.36 – 179.95
+3.7% YoY
|
167.32
154.16 – 180.48
+3.7% YoY
|
191.30
189.43 – 192.62
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kazuaki Hano | Executive Officer | — | male |
| Miki Oguchi | Senior Executive Officer | — | — |
| Naruhiko Sano | Executive Officer | — | — |
| Ryuji Arakawa | President & Representative Director | — | male |
| Shigeki Ohashi | Director & Senior Managing Executive Officer | — | — |
| Soichi Nemoto | Executive Officer | — | male |
| Takashi Sasaki | Executive Officer | — | male |
| Toshikazu Urakabe | Executive Officer | — | — |
| Toshiki Tanaka | Director & Senior Managing Executive Officer | — | — |
| Yusuke Fukujin | Executive Vice President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2784.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
